HQL (abrdn Life Sciences Investors) ROC (Joel Greenblatt) %: % (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HQL abrdn Life Sciences Investors HQL
51 GF Score
Price $22.11
GF Value $62.01
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is abrdn Life Sciences Investors ROC (Joel Greenblatt) %?

abrdn Life Sciences Investors HQL -2.47% 51 ROC (Joel Greenblatt) % is % as of Mar. 2026. GuruFocus rates HQL with a GF Score™ of 51/100 and a GF Value™ of $62.01 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 630 Asset Management companies, abrdn Life Sciences Investors ranks worse than 158730% on this metric.

ROC (Joel Greenblatt) % does not apply to banks and insurance companies.

HQL
51GF Score
abrdn Life Sciences Investors HQL
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a ROC (Joel Greenblatt) % of % mean?
abrdn Life Sciences Investors (HQL) has a ROC (Joel Greenblatt) % of % as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on abrdn Life Sciences Investors and its competitors. According to the industry distribution chart, abrdn Life Sciences Investors ranks #999999 out of 630 companies in the Asset Management industry.
Is abrdn Life Sciences Investors' ROC (Joel Greenblatt) % too high?
abrdn Life Sciences Investors' current ROC (Joel Greenblatt) % is %. Based on the distribution chart, abrdn Life Sciences Investors ranks #999999 out of 630 companies in the Asset Management industry, which is in the bottom quartile relative to peers. Overall, abrdn Life Sciences Investors has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does abrdn Life Sciences Investors' ROC (Joel Greenblatt) % compare to IIM and NOAH?
According to the Asset Management industry distribution chart, abrdn Life Sciences Investors ranks #999999 out of 630 companies for ROC (Joel Greenblatt) %. This places abrdn Life Sciences Investors in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 63.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for an Asset Management company?
The median ROC (Joel Greenblatt) % among Asset Management companies is 63.66, based on 630 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on abrdn Life Sciences Investors and its competitors. For the Asset Management industry, the median ROC (Joel Greenblatt) % is 63.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. abrdn Life Sciences Investors's current ROC (Joel Greenblatt) % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is abrdn Life Sciences Investors stock overvalued right now?
Based on GuruFocus' analysis, abrdn Life Sciences Investors (HQL) is currently considered Significantly Undervalued. The stock's GF Value™ is $62.01, compared to a current price of $22.11 — trading 64.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is %. abrdn Life Sciences Investors' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For abrdn Life Sciences Investors (HQL), the current ROC (Joel Greenblatt) % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is abrdn Life Sciences Investors (HQL) Overvalued in 2026?

Based on GuruFocus' analysis, abrdn Life Sciences Investors stock appears to be undervalued. The current stock price of $22.11 is trading 64.3% below its estimated GF Value™ of $62.01. GuruFocus considers abrdn Life Sciences Investors to be Significantly Undervalued.

Key valuation signals for HQL:

  • ROC (Joel Greenblatt) %: %
  • GF Value™: $62.01 vs. price of $22.11 (64.3% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the HQL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

abrdn Life Sciences Investors Business Description

Address 1900 Market Street, Suite 200, Philadelphia, PA, USA, 19103
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
51GF Score

Get the complete analysis for HQL

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.11
Price
$62.01
GF Value